Ascendis Pharma has reached its target for patient enrolment in a Phase lll trial called heiGHt that seeks to evaluate a treatment for paediatric growth hormone deficiency (GHD).

The randomised, open-label, active-controlled trial expects to assess treatment-naive children with GHD who receive either once-weekly TransCon Growth Hormone or daily Genotropin.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial’s primary endpoint is annualised height velocity at 52 weeks, while primary statistical analysis will be a non-inferiority analysis comparing the two arms.

Ascendis plans to randomise more than 160 subjects in the trial.

“We believe TransCon Growth Hormone can help address the ongoing unmet need for a convenient long-acting growth hormone therapy.”

Ascendis Pharma president and CEO Jan Mikkelsen said: “We have exceeded our target enrolment in this pivotal trial and we look forward to announcing top-line results early next year.

“Our Phase ll data suggested that TransCon Growth Hormone was comparable to a daily growth hormone therapy in terms of efficacy, safety, and tolerability.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As a long-acting growth hormone that delivers unmodified growth hormone, we believe TransCon Growth Hormone can help address the ongoing unmet need for a convenient long-acting growth hormone therapy with efficacy, safety, and tolerability similar to daily alternatives.”

Ascendis added that patients completing the heiGHt trial could be enrolled in the enliGHten trial, which is the company’s open-label long-term extension study.

In addition, Ascendis is carrying out a trial, fliGHt, to examine TransCon Growth Hormone in patients who have previously been treated with daily growth hormone therapy.